Clinical Trial TitleAssessment of the Integrity of the Circadian Regulation of Melatonin and Orexin A in Parkinson's Disease (PD)
Clinical Trial Protocol Description:
The overall goal of this study is to uncover the effects of melatonin and orexin on motor and nonmotor symptoms of Parkinson’s disease (PD) by looking at the integrity of their regulatory response. To achieve this, this study will track the baseline levels and physiological adjustment of both neurotransmitters as a response to standardized simulated daylight cycles.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are English-speaking, between 50 and 80 years of age.
- Have a diagnosis of Parkinson’s disease.
- Are able to keep a log at home, which can be done personally or with someone else’s assistance.
- Have a working refrigerator with a freezer at home to store saliva samples overnight.
You will be excluded from the study if any of the following criteria apply to you:
- Have vascular Parkinson’s disease.
- Have major neurocognitive disorder.
- Have blindness, history of persistent aphasia, major strokes with motor deficits, stage 3 and 4 chronic kidney disease, uncontrolled type 1 or type 2 Diabetes Mellitus, active substance use disorders, eating disorders, schizophrenia.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.